Rezolute (RZLT) Competitors $6.30 +0.43 (+7.33%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$6.36 +0.06 (+0.87%) As of 07/25/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RZLT vs. IMCR, TARS, APGE, OCUL, VCEL, SPRY, ARQT, ADPT, SDGR, and JANXShould you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Immunocore (IMCR), Tarsus Pharmaceuticals (TARS), Apogee Therapeutics (APGE), Ocular Therapeutix (OCUL), Vericel (VCEL), ARS Pharmaceuticals (SPRY), Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), Schrodinger (SDGR), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry. Rezolute vs. Its Competitors Immunocore Tarsus Pharmaceuticals Apogee Therapeutics Ocular Therapeutix Vericel ARS Pharmaceuticals Arcutis Biotherapeutics Adaptive Biotechnologies Schrodinger Janux Therapeutics Rezolute (NASDAQ:RZLT) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Is RZLT or IMCR more profitable? Rezolute has a net margin of 0.00% compared to Immunocore's net margin of -6.48%. Immunocore's return on equity of -5.86% beat Rezolute's return on equity.Company Net Margins Return on Equity Return on Assets RezoluteN/A -70.09% -63.08% Immunocore -6.48%-5.86%-2.09% Do analysts prefer RZLT or IMCR? Rezolute currently has a consensus target price of $11.83, indicating a potential upside of 87.83%. Immunocore has a consensus target price of $58.89, indicating a potential upside of 67.44%. Given Rezolute's stronger consensus rating and higher probable upside, analysts plainly believe Rezolute is more favorable than Immunocore.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Immunocore 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55 Does the media prefer RZLT or IMCR? In the previous week, Rezolute had 2 more articles in the media than Immunocore. MarketBeat recorded 4 mentions for Rezolute and 2 mentions for Immunocore. Immunocore's average media sentiment score of 1.30 beat Rezolute's score of 0.50 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunocore 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, RZLT or IMCR? Rezolute has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Do institutionals & insiders have more ownership in RZLT or IMCR? 83.0% of Rezolute shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 18.4% of Rezolute shares are held by company insiders. Comparatively, 10.4% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, RZLT or IMCR? Immunocore has higher revenue and earnings than Rezolute. Immunocore is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRezoluteN/AN/A-$68.46M-$1.15-5.48Immunocore$310.20M5.70-$51.09M-$0.43-81.79 SummaryRezolute and Immunocore tied by winning 8 of the 16 factors compared between the two stocks. Get Rezolute News Delivered to You Automatically Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RZLT vs. The Competition Export to ExcelMetricRezoluteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$510.67M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.69%4.01%P/E Ratio-5.4821.1828.1020.06Price / SalesN/A283.55428.7189.10Price / CashN/A42.7636.2258.56Price / Book2.888.378.665.87Net Income-$68.46M-$55.19M$3.25B$258.55M7 Day Performance16.88%5.88%4.22%3.73%1 Month Performance46.17%17.33%10.51%11.75%1 Year Performance34.62%4.42%34.40%18.02% Rezolute Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RZLTRezolute2.5381 of 5 stars$6.30+7.3%$11.83+87.8%+34.6%$510.67MN/A-5.4840News CoverageAnalyst RevisionIMCRImmunocore1.4778 of 5 stars$36.93+1.7%$58.89+59.5%-12.4%$1.82B$310.20M-85.88320News CoveragePositive NewsTARSTarsus Pharmaceuticals1.522 of 5 stars$42.18-2.5%$66.67+58.1%+47.0%$1.82B$182.95M-15.4550APGEApogee Therapeutics3.3908 of 5 stars$39.11-0.5%$99.00+153.1%-16.1%$1.81BN/A-10.8691Positive NewsOCULOcular Therapeutix3.8788 of 5 stars$11.52+1.7%$17.33+50.5%+47.5%$1.80B$63.72M-10.02230VCELVericel3.6821 of 5 stars$35.46+0.3%$61.14+72.4%-22.4%$1.78B$237.22M1,178.00300News CoveragePositive NewsUpcoming EarningsSPRYARS Pharmaceuticals3.085 of 5 stars$17.85-0.4%$31.00+73.7%+59.7%$1.76B$89.15M-111.5690Positive NewsARQTArcutis Biotherapeutics2.1447 of 5 stars$14.34-2.2%$18.80+31.1%+47.1%$1.75B$196.54M-13.79150Positive NewsAnalyst ForecastADPTAdaptive Biotechnologies2.7823 of 5 stars$10.31-0.8%$10.57+2.5%+148.3%$1.58B$178.96M-10.74790Positive NewsSDGRSchrodinger2.0193 of 5 stars$22.82+6.4%$32.75+43.5%-0.3%$1.57B$207.54M-8.68790Upcoming EarningsGap UpJANXJanux Therapeutics2.471 of 5 stars$26.08-1.2%$91.89+252.3%-39.3%$1.56B$10.59M-19.1830 Related Companies and Tools Related Companies IMCR Alternatives TARS Alternatives APGE Alternatives OCUL Alternatives VCEL Alternatives SPRY Alternatives ARQT Alternatives ADPT Alternatives SDGR Alternatives JANX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RZLT) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RZLT Stock Alerts